Marbofloxacin hydrochloride
(Synonyms: 盐酸马波沙星) 目录号 : GC36538
A fluoroquinolone antibiotic
Cas No.:115551-26-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Marbofloxacin is a fluoroquinolone antibiotic that is active against P. multocida in vitro (MIC = 0.016 μg/ml).1 It exhibits broad-spectrum antibacterial activity mediated by the inhibition of DNA gyrase, with MIC values ranging from 0.016 to 0.4 and 0.19 to 1.7 ?g/ml against various Gram-negative and Gram-positive bacterial isolates, respectively.2 Intramuscular administration of marbofloxacin (2 mg/kg) after infection prevents the formation of pulmonary lesions in a bovine calf model of M. haemolytica A1 pneumonia.3 Oral administration of marbofloxacin (2 mg/kg per day) also exhibits antileishmanial activity in a canine model of leishmaniasis, decreasing parasitic load by 72%.4 Formulations containing marbofloxacin have been used in the veterinary treatment of bacterial infections.
1.Ferran, A.A., Toutain, P.L., and Bousquet-Mélou, A.Impact of early versus later fluoroquinolone treatment on the clinical; microbiological and resistance outcomes in a mouse-lung model of Pasteurella multocida infectionVet. Microbiol.148(2-4)292-297(2011) 2.Spreng, M., Deleforge, J., Thomas, V., et al.Antibacterial activity of marbofloxacin. A new fluoroquinolone for veterinary use against canine and feline isolatesJ. Vet. Pharmacol. Ther.18(4)284-289(1995) 3.Lhermie, G., Ferran, A.A., Assié, S., et al.Impact of timing and dosage of a fluoroquinolone treatment on the microbiological, pathological, and clinical outcomes of calves challenged with Mannheimia haemolyticaFront. Microbiol.237(7)(2016) 4.Pineda, C., Aguilera-Tejero, E., Morales, M.C., et al.Treatment of canine leishmaniasis with marbofloxacin in dogs with renal diseasePLoS One12(10)e0185981(2017)
| Cas No. | 115551-26-3 | SDF | |
| 别名 | 盐酸马波沙星 | ||
| Canonical SMILES | O=C(C(C1=O)=CN2N(C)COC3=C(N4CCN(C)CC4)C(F)=CC1=C32)O.Cl | ||
| 分子式 | C17H20ClFN4O4 | 分子量 | 398.82 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5074 mL | 12.537 mL | 25.074 mL |
| 5 mM | 0.5015 mL | 2.5074 mL | 5.0148 mL |
| 10 mM | 0.2507 mL | 1.2537 mL | 2.5074 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Determination of trace antibiotics in water and milk via preconcentration and cleanup using activated carbons
Food Chem 2022 Aug 15;385:132695.PMID:35338997DOI:10.1016/j.foodchem.2022.132695.
CPAC-SPE-HPLC (coconut powdered activated carbon -SPE- HPLC) has been developed for the determination of antibiotic (ABX), sulfamonomethoxine sodium (SMM), oxytetracycline (OTC), ceftiofur hydrochloride (CEF) and Marbofloxacin (MAR), in water and milk. Over 99.0% SMM and OTC were recovered from 20 mL of 0.5 μg/mL ABX solution using 10 mg-CPAC for adsorption and 2 mL of 30% NH4OH/EtOH (1/19 v/v) for elution. Similarly, over 99.0% CEF and MAR were recovered using 15 mg-CPAC and 2 mL of 30% NH4OH/n-PrOH (1/19 v/v). Moreover, the recovery efficiencies of various ABX from 5 to 80 mL of 0.02-2.00 μg/mL medicated milk containing 10 mM EDTA are ordered as follows: OTC (99.3%), SMM (99.1%) > CEF (68.9%) > MAR (61.4%). No interference towards HPLC analysis were observed with elution using 2 mL of 30% NH4OH/EtOH (1/19 v/v). Furthermore, much lower limit of detections (0.02 μg/mL) than the maximum residual limits from European Commission (0.075-0.100 μg/mL) were obtained.
Removal of antibiotics from milk via ozonation in a vortex reactor
J Hazard Mater 2022 Oct 15;440:129642.PMID:35961077DOI:10.1016/j.jhazmat.2022.129642.
Antibiotics (ABX) residues occur frequently in milk, causing considerable wastage of medicated milk and serious economic losses, and making the issue a burden for the dairy industry. Improper disposal of medicated milk harms dairy production, animal welfare, and the environment. This work studies the use of ozonation in a vortex reactor for removing ceftiofur hydrochloride (CEF), sulfamonomethoxine sodium (SMM), Marbofloxacin (MAR) and oxytetracycline (OTC) from milk. In terms of residual concentration, O3 efficiency and the degradation kinetics of the various O3-involving processes in the vortex reactor, ABX removal via ozonation is better using stronger vortexing, which induces hydrodynamic cavitation. CEF undergoes the fastest degradation, followed by SMM, MAR, and OTC. High ABX hydrophobicity favors ABX degradation via ozonation, O3/H2O2, and O3/Na2S2O8. ABX oxidation by •OH at the O3 gas-bubble/milk interface is the principle degradation pathway, except for MAR. ABX degradation follows pseudo-first-order kinetics and is affected by initial ABX concentration, O3 concentration/flow rate, reaction temperature, and milk components to varying degrees. Under optimal ozonation conditions, ABX residues meet the maximum limits as set by the European Commission and no antimicrobial activity was observed. The decontaminated milk was therefore suggested to be reused as calf food, animal feed, organic fertilizer, etc.
Chemiluminescence competitive indirect enzyme immunoassay for 20 fluoroquinolone residues in fish and shrimp based on a single-chain variable fragment
Anal Bioanal Chem 2013 Sep;405(23):7477-84.PMID:23842902DOI:10.1007/s00216-013-7174-9.
A chemiluminescent competitive indirect enzyme-linked immunosorbent assay, based on a mutant single-chain variable fragment (scFv), was developed to detect a broad range of fluoroquinolones (FQs) in fish and shrimp matrices. In this study, the best scFvC4A9H1_mut2 was adopted, which showed 10-fold improved affinity to sarafloxacin (SAR), difloxacin (DIF), and trovafloxacin (TRO), while the affinity to other FQs was fully inherited from wild-type scFvC4A9H1. In the optimized generic test, scFvC4A9H1_mut2 in combination with norfloxacin-ovalbumin conjugate and horseradish peroxidase-labeled anti-c-myc 9E10 antibody showed 50 % binding inhibition (IC50) at 0.12 μg kg(-1) for norfloxacin in buffer. Screening for the class of FQ antibiotics is accomplished using a simple, rapid extraction carried out with ethanol/acetic acid (99:1, v/v). This common extraction was able to detect 20 FQ residues such as s ciprofloxacin (CIP), danofloxacin, DIF, enoxacin, enrofloxacin (ENR), fleroxacin, amifloxacin, flumequine, levofloxacin, lomefloxacin hydrochloride, Marbofloxacin, norfloxacin (NOR), ofloxacin, orbifloxacin, pazufloxacin, pefloxacin-d5 (PEF), prulifloxacin, SAR, sparfloxacin, and TRO in fish and shrimp. The limit of detection (LOD) for NOR was 0.2 μg kg(-1) and the LODs for CIP and ENR were all <0.2 μg kg(-1). Values of LODs inferred from the cross-reactivity data will range from approximately 0.23 μg kg(-1) for PEF to 2.1 μg kg(-1) for TRO. Field fish and shrimp samples were analyzed and compared to the results obtained from liquid chromatography tandem mass spectrometric method. All five instances (from 0.25 to 15.6 μg kg(-1)) in which FQs were present at concentrations near or above the assay LOD were identified as positive by the newly developed assay, demonstrating the usefulness of this assay as a screening tool.